1
|
Zakkula A, Tripathy HK, Bestha RM, Vinod AB, Kiran V, Dittakavi S, Mullangi R. Validated HPLC-UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice. Biomed Chromatogr 2023; 37:e5587. [PMID: 36680551 DOI: 10.1002/bmc.5587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 01/10/2023] [Accepted: 01/18/2023] [Indexed: 01/22/2023]
Abstract
Paxalisib is a pan-PI3K and mTOR inhibitor, currently entering into Phase II clinical trials as a potential drug to treat glioblastoma patients. We report the development and validation of a high-performance liquid chromatography (HPLC) method for the quantitation of paxalisib in mouse plasma as per the US Food and Drug Administration regulatory guidelines. From the mouse plasma, paxalisib and the internal standard (IS; filgotinib) were extracted using ethyl acetate as an extraction solvent. The chromatographic separation of paxalisib and the IS was accomplished on a Symmetry C18 (250 × 4.6 mm, 5.0 μm) column maintained at 40°C using 10 mm ammonium formate and acetonitrile in gradient conditions at a 0.8 ml/min flow-rate. The injection volume was 20 μl. The elution was monitored using a photo-diode array detector set at λmax 280 nm. Paxalisib and the IS eluted at 6.5 and 5.9 min, respectively with a total run time of 10 min. The calibration curve was linear over the range of 111-4,989 ng/ml. Inter- and intraday precision and accuracy, stability studies, dilution integrity and incurred sample reanalysis were investigated and the results met the acceptance criteria. The validated HPLC method was extended to assess the pharmacokinetic parameters of paxalisib in mice.
Collapse
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| | | | - Rama Murthi Bestha
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| | - A B Vinod
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India
| |
Collapse
|
2
|
Tripathy HK, Kiran V, Zakkula A, A B V, Bestha RM, Dittakavi S, Mullangi R. Validated LC-MS/MS method for the determination of copanlisib in mouse dried blood spots. Biomed Chromatogr 2023; 37:e5548. [PMID: 36385469 DOI: 10.1002/bmc.5548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 11/13/2022] [Accepted: 11/14/2022] [Indexed: 11/18/2022]
Abstract
Copanlisib is a dual PI3K-δ inhibitor, used in follicular lymphoma treatment. In this research, we report a validated LC-MS/MS method for quantifying copanlisib from a mouse dried blood spot (DBS). We validated the method in line with the guidelines of the US Food and Drug Administration. The liquid-liquid extraction technique was used to extract copanlisib from the DBS discs. We used an Atlantis dC18 column and isocratic mobile phase for the chromatographic separation of copanlisib and the internal standard (idelalisib). The flow was 0.90 ml/min. Under the optimized chromatographic conditions, the retentions of copanlisib and the internal standard were 0.98 and 0.93 min, respectively. Each injection total run time was 2.50 min. The MS/MS ion transitions monitored were m/z 481.31 → 128.00 and 416.10 → 176.10 for copanlisib and the internal standard (IS) idelalisib, respectively. We have used a broad calibration range (1.01-4,797 ng/ml) with a determination coefficient (r2 ) of 0.997. All of the evaluated parameters met the acceptance criteria. Hematocrit did not influence the DBS copanlisib concentrations. We have used the validated method to derive the intravenous pharmacokinetic parameters by quantifying copanlisib in mouse plasma.
Collapse
Affiliation(s)
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| | - Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| | - Vinod A B
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| | - Rama Murthy Bestha
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India
| |
Collapse
|
3
|
Tripathy HK, S V Nair M, Bestha RM, Kiran V, Dittakavi S, Mullangi R. Validated LC-MS/MS method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice. Biomed Chromatogr 2022; 36:e5387. [PMID: 35470912 DOI: 10.1002/bmc.5387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 04/20/2022] [Accepted: 04/22/2022] [Indexed: 11/08/2022]
Abstract
In this, we report the development and validation of an LC-MS/MS method for the simultaneous quantitation of bendamustine and copanlisib in mouse plasma as per the FDA regulatory guidelines. The sample processing involves extraction of bendamustine and copanlisib along with internal standard (IS; warfarin) from 50 μL mouse plasma using a liquid-liquid extraction method. The chromatographic separation of bendamustine, copanlisib, and the IS was achieved on a Atlantis C18 column using an isocratic mobile phase (5 mM ammonium acetate:methanol; 20:80, v/v). Bendamustine, copanlisib and the IS eluted at 0.88, 1.39 and 0.74 min, respectively with a total run time of 2.5 min. The calibration curve ranged from 3.99-2996 and 4.33-3248 ng/mL for bendamustine and copanlisib, respectively. Inter- and intraday precision and accuracy, stability in processed samples and up on storage, dilution integrity and incurred sample reanalysis were investigated for both the analytes. The intra- and inter-day precisions were in the ranges of 2.01-5.05 and 2.74-6.13% and 1.98-7.64 and 8.62-9.04% for bendamustine and copanlisib, respectively. Stability studies showed that both analytes were stable on bench top for 6 h, in auto-sampler for 24 and at -80°C for 30 days. The validated method was successfully applied to a pharmacokinetic study in mice.
Collapse
Affiliation(s)
| | | | - Rama Murthy Bestha
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shameerpet, Hyderabad, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shameerpet, Hyderabad, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shameerpet, Hyderabad, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shameerpet, Hyderabad, India
| |
Collapse
|
4
|
Siddesh A, Sriram D, Zakkula A, Kumar R, Dittakavi S, Zainuddin M, Trivedi RK, Mullangi R. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats. Biomed Chromatogr 2021; 35:e5015. [PMID: 33125719 DOI: 10.1002/bmc.5015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 10/16/2020] [Accepted: 10/22/2020] [Indexed: 11/07/2022]
Abstract
Phosphatidylinositol 3-kinase (PI3K) inhibitors are a novel class of anticancer drugs that are approved to treat various malignancies. We report the development and validation of a HPLC method for the simultaneous quantitation of three PI3K inhibitors, namely copanlisib, duvelisib and idelalisib, in rat plasma as per the regulatory guidelines of the United States Food and Drug Administration. The method involves extraction of copanlisib, duvelisib and idelalisib along with an internal standard (IS; filgotinib) from rat plasma (100 μL) using a liquid-liquid extraction process. The chromatographic separation of the analytes was achieved using step-wise gradient elution on a Hypersil Gold C18 column. The UV detection wavelength was set at λmax = 280 nm. Copanlisib, duvelisib, idelalisib and the IS eluted at 7.16, 12.6, 11.9 and 9.86 min, respectively, with a total run time of 15 min. The calibration curve ranged from 50 to 5000 ng/mL for all the analytes. Inter- and intra-day precision and accuracy, stability studies, dilution integrity and incurred sample reanalysis were investigated for all three analytes, and the results met the acceptance criteria. The validated HPLC method was successfully applied to a pharmacokinetic study in rats.
Collapse
Affiliation(s)
- Anup Siddesh
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Dhurvu Sriram
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Rajnish Kumar
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | | | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Ravi Kumar Trivedi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| |
Collapse
|
5
|
Madhyastha N, Samantha SK, Dittakavi S, Markose M, Mallurwar SR, Zainuddin M, Mullangi R. Validated HPLC‐MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice. Biomed Chromatogr 2021; 35:e5043. [DOI: 10.1002/bmc.5043] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 10/28/2020] [Accepted: 11/30/2020] [Indexed: 11/08/2022]
Affiliation(s)
| | | | | | - Meenu Markose
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | | | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| |
Collapse
|
6
|
Saini NK, Gabani BB, Todmal U, Sulochana SP, Kiran V, Zainuddin M, Balaji N, Polina SB, Srinivas NR, Mullangi R. Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients. Drug Metab Lett 2021; 14:54-65. [PMID: 32436836 DOI: 10.2174/1872312814666200521091236] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 02/25/2020] [Accepted: 04/01/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND Darolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. Hitherto, no stereoselective pharmacokinetic data have been published pertaining to darolutamide and its diastereomers in animals or humans. The key aims of the experiment were to examine darolutamide, S,S-darolutamide and S,R-darolutamide with respect to (a) assessment of in vitro metabolic stability and protein binding and (b) characterization of in vivo oral and intravenous pharmacokinetics in mice. METHODS In vitro (liver microsomes stability and protein binding) and in vivo experiments (oral/intravenous dosing to mice) were carried out using darolutamide, S,S-darolutamide and S,Rdarolutamide. Besides, tissue levels of darolutamide, S,S-darolutamide and S,R-darolutamide were measured following oral and intravenous dosing. Appropriate plasma/tissue samples served to determine the pharmacokinetics of various analytes in mice. Liquid chromatography in tandem with mass spectrometry procedures enabled the delineation of the plasma pharmacokinetics, in vitro and tissue uptake data of the various analytes. RESULTS Chiral inversion was absent in the metabolic stability study. However, darolutamide showed profound stereoselectivity (S,S-darolutamide greater than S,R-darolutamide) after either intravenous or oral dosing. S,R-darolutamide but not S,S-darolutamide showed conversion to its antipode post oral and intravenous dosing to mice. Regardless of oral or intravenous dosing, active keto darolutamide formation was evident after administration of darolutamide, S,S-darolutamide or S,R- darolutamide. Tissue data supported the observations in plasma; however, tissue exposure of darolutamide, S,Sdarolutamide and S,R-darolutamide was much lower as compared to plasma. CONCLUSION In lieu of the human pharmacokinetic data, although the administration of diastereomeric darolutamide was justified, it is proposed to delineate the clinical pharmacokinetics of S,Rdarolutamide and S,S-darolutamide relative to darolutamide in future clinical pharmacology studies.
Collapse
Affiliation(s)
- Neeraj K Saini
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Bhavesh B Gabani
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Umesh Todmal
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Narayanan Balaji
- Analytical Department, Yeshwanthpur, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Sai B Polina
- Chemistry Department, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd., Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| |
Collapse
|
7
|
Abstract
Lipids are a complex and critical heterogeneous molecular entity, playing an intricate and key role in understanding biological activities and disease processes. Lipidomics aims to quantitatively define the lipid classes, including their molecular species. The analysis of the biological tissues and fluids are challenging due to the extreme sample complexity and occurrence of the molecular species as isomers or isobars. This review documents the overview of lipidomics workflow, beginning from the approaches of sample preparation, various analytical techniques and emphasizing the state-of-the-art mass spectrometry either by shotgun or coupled with liquid chromatography. We have considered the latest ion mobility spectroscopy technologies to deal with the vast number of structural isomers, different imaging techniques. All these techniques have their pitfalls and we have discussed how to circumvent them after reviewing the power of each technique with examples..
Collapse
Affiliation(s)
| | - Ramesh Mullangi
- Laxai Life Sciences Pvt Ltd, MN Park, Genome Valley, Shamirpet, Hyderabad-500 078, India
| |
Collapse
|
8
|
Kiran V, Dixit A, Gabani BB, Srinivas NR, Mullangi R. Novel methodology to perform incurred sample reanalysis on dried blood spot cards: Experimental data using darolutamide and filgotinib. Biomed Chromatogr 2020; 34:e4938. [PMID: 32614457 DOI: 10.1002/bmc.4938] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 06/19/2020] [Accepted: 06/29/2020] [Indexed: 01/01/2023]
Abstract
Different options on performing incurred sample reanalysis (ISR) on dried blood spot (DBS) cards were investigated using drugs belonging to various therapeutic areas: (a) darolutamide (to treat prostate cancer) and (b) filgotinib (to treat rheumatoid arthritis). The proposed novel methodology included the generation of half-DBS and quarter-DBS discs after initial blood collection using the full-DBS discs. Accordingly, blood collection via DBS was performed in male BALB/c mice following intravenous and oral dosing of darolutamide; in male Sprague Dawley rats following intravenous and oral dosing of filgotinib. The ISR data generated from the full-DBS disc, half-DBS disc and quarter-DBS disc were compared for the assessment of the proposed methodology. Quantification of darolutamide and filgotinib was accomplished using liquid chromatography-electrospray ionization/tandem mass spectrometry methods. Darolutamide and filgotinib ISR samples, which were collected and prepared using full-, half- and quarter-DBS discs, met the acceptance criteria for ISR analysis. In conclusion, this is the first report showing a viable tool for the performance of ISR on DBS cards. The use of quarter- or half-DBS discs would aid in not only ISR but also in long-term storage experiments of analytes because it would avoid the need for additional blood sampling in patients.
Collapse
Affiliation(s)
- Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, Karnataka, India
| | - Abhishek Dixit
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, Karnataka, India
| | - Bhavesh Babulal Gabani
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, Karnataka, India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, Karnataka, India
| |
Collapse
|
9
|
Sulochana SP, Trivedi RK, Srinivas NR, Mullangi R. A concise review of bioanalytical methods of small molecule immuno-oncology drugs in cancer therapy. Biomed Chromatogr 2020; 35:e4996. [PMID: 33047346 DOI: 10.1002/bmc.4996] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 09/21/2020] [Accepted: 09/24/2020] [Indexed: 01/13/2023]
Abstract
Immuno-oncology (IO) is an emerging option to treat cancer malignancies. In the last two years, IO has accounted for more than 90% of the new active drugs in various therapeutic indications of oncology drug development. Bioanalytical methods used for the quantitation of various IO small molecule drugs have been summarized in this review. The most commonly used are HPLC and LC-MS/MS methods. Determination of IO drugs from biological matrices involves drug extraction from the biological matrix, which is mostly achieved by simple protein precipitation, liquid-liquid extraction and solid-phase extraction. Subsequently, quantitation is usually achieved by LC-MS/MS, but HPLC-UV has also been employed. The bioanalytical methods reported for each drug are briefly discussed and tabulated for easy access. Our review indicates that LC-MS/MS is a versatile and reliable tool for the sensitive, rapid and robust quantitation of IO drugs.
Collapse
Affiliation(s)
- Suresh P Sulochana
- Pharmacokinetics and Drug Metabolism Group, University of Mississippi, MS, USA
| | | | | | | |
Collapse
|
10
|
Tripathy HK, Manju NSV, Dittakavi S, Zakkula A, Mullangi R. DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2020; 71:36-42. [PMID: 32992346 DOI: 10.1055/a-1252-2476] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Idelalisib is a selective and second-generation PI3K-δ inhibitor, approved for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. In this paper, we present a fully validated dried blood spot (DBS) method for the quantitation of idelalisib from mice blood using an LC-MS/MS, which was operated under multiple reaction monitoring mode. To the punched DBS discs, acidified methanol enriched with internal standard (IS; larotrectinib) was added and extracted using tert-butyl methyl ether as an extraction solvent with sonication. Chromatographic separation of idelalisib and the IS was achieved on an Atlantis dC18 column using a mixture of 10 mM ammonium formate:acetonitrile (25:75, v/v). The flow-rate and injection volume were 0.80 mL/min and 2.0 µL, respectively. Idelalisib and the IS were eluted at ~0.98 and 0.93 min, respectively and the total run time was 2.00 min. Idelalisib and the IS were analyzed using positive ion scan mode and parent-daughter mass to charge ion (m/z) transition of 416.1→176.1 and 429.1→342.1, respectively was used for the quantitation. The calibration range was 1.01-4 797 ng/mL. No matrix effect and carry over were observed. Haematocrit did not influence DBS idelalisib concentrations. All the validation parameters met the acceptance criteria. The applicability of the validated method was shown in a mice pharmacokinetic study.
Collapse
Affiliation(s)
| | - Nair S V Manju
- Karnataka College of Pharmacy, Thirumenahalli, Bangalore
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore
| | - Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore
| |
Collapse
|
11
|
Dittakavi S, Jat RK, Mullangi R. A Validated DBS Method for Quantitation of a Novel Mutant IDH1/2 Inhibitor, Vorasidenib Using 10 μL Mice Blood: Application to a Pharmacokinetic Study in Mice. CURR PHARM ANAL 2020. [DOI: 10.2174/1573412915666190802163644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Vorasidenib is a pan-IDH inhibitor, undergoing clinical trials for the treatment
of acute myeloid leukemia.
Methods:
In this paper, we present the data of method validation to quantify vorasidenib in the mice
blood mice using dried blood spot (DBS) method on LC-MS/MS as per FDA bioanalytical method validation
guideline. Using methanol (enriched with internal standard) as an extraction solvent followed by
sonication, vorasidenib was extracted from DBS quality control samples, calibration curve samples and
pharmacokinetic study samples. Baseline separation of vorasidenib and the IS in a 2.0 μL injected sample
was accomplished by delivering 0.2% formic acid and acetonitrile (25:75, v/v) at a constant flowrate
(1.00 mL/min) on a C18 column. The total run time was 2.0 min. Using the transition pair of m/z
415.4→260.4 for vorasidenib and m/z 583.1→186.1 for the IS, the quantitation was performed. The
method linearity range was 1.00-3008.00 ng/mL.
Results:
The recovery of vorasidenib ranged between 71.28%-78.14% across the tested concentrations.
No matrix effect was seen. Intra- and inter-day precisions were ≤7.23% and intra- and inter-accuracies
ranged between 97.1%-107%. Vorasidenib was stable for three freeze/thaw cycles, up to 7 days at room
temperature and for one month at -80°C. Following intravenous and oral administration of vorasidenib
to mice, it was quantifiable up to 72 h. The oral bioavailability was 51.6%.
Conclusions:
All the validation parameters met the acceptance criteria as specified in the FDA regulatory
guideline. The results suggest that validated DBS method can be used for pharmacokinetic studies in
mice to characterize the pharmacokinetic parameters of vorasidenib post intravenous and oral administration.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2nd Stage, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Rakesh Kumar Jat
- Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu-Churu Road, Chudela, Jhunjhunu- 333001, Rajasthan, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2nd Stage, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| |
Collapse
|
12
|
Gabani BB, Dixit A, Kiran V, Bestha RM, Narayanan B, Srinivas NR, Mullangi R. Enantioselective in vitro ADME, absolute oral bioavailability, and pharmacokinetics of (-)-lumefantrine and (+)-lumefantrine in mice. Xenobiotica 2020; 51:202-209. [PMID: 32930648 DOI: 10.1080/00498254.2020.1823523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Lumefantrine (LFN) is a chiral antimalarial drug. Enantioselective in vitro attributes and absolute oral pharmacokinetics for (-)-LFN and (+)-LFN have been characterized in mice. No stereoselectivity was seen with either of the enantiomers when compared with rac-LFN in the executed in vitro studies (solubility, metabolic stability, protein binding, permeability and blood partitioning). Post intravenous or oral administration of rac-LFN, the AUC0-∞ and MRT of (+)-LFN was higher over (-)-LFN, which is reflected in higher clearance value for (-)-LFN. Following (-)-LFN intravenous administration to mice, the key PK parameters were comparable to (-)-LFN from rac-LFN; however, post intravenous administration of (+)-LFN alone to mice, the AUC0-∞ was 1.3-fold higher than (+)-LFN from rac-LFN. Similarly, post oral administration of (-)-LFN to mice, both AUC0-∞ and Cmax were 1.3-fold higher than (-)-LFN from rac-LFN. On other hand, (+)-LFN showed 1.4-fold higher AUC0-∞ and 1.7-fold higher Cmax post oral administration over (+)-LFN from rac-LFN.
Collapse
Affiliation(s)
- Bhavesh Babulal Gabani
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Bangalore, India
| | - Abhishek Dixit
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Bangalore, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Bangalore, India
| | - Ram Murthi Bestha
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Bangalore, India
| | - Balaji Narayanan
- Analytical Department, Jubilant Biosys, Industrial Suburb, Bangalore, India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Bangalore, India
| |
Collapse
|
13
|
Kiran V, Balaji N, Gabani BB, Bajantri M, Chandran R, Dixit A, Srinivas NR, Mullangi R. Enantioselective LC–ESI–MS/MS method for quantitation of (−)‐lumefantrine and (+)‐lumefantrine in mice plasma and application to a pharmacokinetic study. Biomed Chromatogr 2020; 34:e4879. [DOI: 10.1002/bmc.4879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 05/04/2020] [Accepted: 05/06/2020] [Indexed: 11/07/2022]
Affiliation(s)
- Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| | - Narayanan Balaji
- Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| | - Bhavesh Babulal Gabani
- Drug Metabolism and Pharmacokinetics, Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| | | | - Rajesh Chandran
- Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| | - Abhishek Dixit
- Drug Metabolism and Pharmacokinetics, Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Department of Analytical Chemistry, Jubilant Biosys Ltd Bangalore India
| |
Collapse
|
14
|
Tripathy HK, Manju NSV, Dittakavi S, Bestha RM, Mullangi R. A dried blood spot assay with HPLC-MS/MS for the determination of larotrectinib in mouse blood and its application to a pharmacokinetic study. Biomed Chromatogr 2020; 34:e4953. [PMID: 32706402 DOI: 10.1002/bmc.4953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 07/15/2020] [Accepted: 07/21/2020] [Indexed: 11/07/2022]
Abstract
Larotrectinib is a first-generation tropomyosin kinase inhibitor, approved for the treatment of solid tumors. In this paper, we present a validated dried blood spot (DBS) method for the quantitation of larotrectinib from mouse blood using HPLC-MS/MS, which was operated under multiple reaction monitoring mode. To the DBS disc cards, acidified methanol enriched with internal standard (IS; enasidenib) was added and extracted using tert-butyl methyl ether as an extraction solvent with sonication. Chromatographic separation of larotrectinib and the IS was achieved on an Atlantis dC18 column using 10 mm ammonium formate-acetonitrile (30:70, v/v) delivered at a flow-rate of 0.80 ml/min. Under these optimized conditions, the retention times of larotrectinib and the IS were ~0.93 and 1.37 min, respectively. The total run time was 2.50 min. Larotrectinib and the IS were analyzed using positive ion scan mode and parent-daughter mass to charge ion (m/z) transitions of 429.1 → 342.1 and 474.1 → 267.1, respectively, were used for the quantitation. The calibration range was 1.06-5,080 ng/ml. No matrix effect or carryover was observed. Hematocrit did not influence DBS larotrectinib concentrations. All of the validation parameters met the acceptance criteria. The applicability of the validated method was shown in a mouse pharmacokinetic study.
Collapse
Affiliation(s)
| | | | | | - Ram Murthi Bestha
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| |
Collapse
|
15
|
Gabani BB, Saini NK, Jairam RK, Shrinivas P, Trivedi RK, Srinivas NR, Mullangi R. Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. Biomed Chromatogr 2020; 34:e4939. [DOI: 10.1002/bmc.4939] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 06/24/2020] [Accepted: 06/29/2020] [Indexed: 12/19/2022]
Affiliation(s)
| | - Neeraj Kumar Saini
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | - Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | - Pavan Shrinivas
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | - Ravi Kumar Trivedi
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics Jubilant Biosys Ltd Bangalore India
| |
Collapse
|
16
|
Tamizharasan N, Gajendran C, Kristam R, Sulochana SP, Sivanandhan D, Mullangi R, Mathivathanan L, Hallur G, Suresh P. Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors. Bioorg Chem 2020; 99:103800. [DOI: 10.1016/j.bioorg.2020.103800] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 03/18/2020] [Accepted: 03/24/2020] [Indexed: 02/06/2023]
|
17
|
Gabani BB, Sulochana SP, Siddesh AH, Kiran V, Saini NK, Samanta SK, Hallur MS, Rajagopal S, Mullangi R. Validated LC-MS/MS Method for Simultaneous Quantitation of
SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic
Study. Drug Res (Stuttg) 2020; 70:325-332. [DOI: 10.1055/a-1164-6123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
AbstractSAFit-1 and SAFit-2 are selective FKBP51 (FK506-binding protein 51) ligands. In
this paper, we present the development and validation data of an
LC-MS/MS method for the simultaneous quantitation of SAFit-1 and SAFit-2
in mice plasma as per FDA regulatory guideline. SAFit-1 and SAFit-2 along with
internal standard were extracted from mice plasma using liquid-liquid extraction
method. Chromatographic resolution of SAFit-1, SAFit-2 and the internal standard
(warfarin) was achieved on an X-Terra phenyl column using 0.2% formic
acid:acetonitrile (20:80, v/v) as an eluent, which was delivered at a
flow-rate of 0.9 mL/min. The MS/MS ion transitions monitored
were m/z 748.4→420.4, 803.7→384.3 and 309.2
→163.2 for SAFit-1, SAFit-2 and the internal standard, respectively. The
linearity range was 2.45–2446 ng/mL for both SAFit-1 and
SAFit-2. The intra- and inter-day accuracy and intra- and inter-day precision
were in the range of 0.90–1.07 and 2.38–10.8%,
respectively for SAFit-1; 0.97–1.15 and 0.23–12.5%,
respectively for SAFit-2. Both SAFit-1 and SAFit-2 were found to be stable in
stability studies (up to three freeze-thaw cycles and for long-term at
−80°C for 30 days) and processed (bench-top for 3 h and in
in-injector for 16 h) samples. The application of the validated method was shown
in a pharmacokinetic study in mice.
Collapse
Affiliation(s)
| | | | - Anup H.A. Siddesh
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bengaluru,
India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bengaluru,
India
| | | | | | | | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bengaluru,
India
| |
Collapse
|
18
|
Dixit A, Kiran V, Gabani BB, Mullangi R. Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats. ADMET DMPK 2020; 8:139-148. [PMID: 35300367 PMCID: PMC8915582 DOI: 10.5599/admet.796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 04/23/2020] [Indexed: 11/29/2022] Open
Abstract
Filgotinib is a selective JAK1 (Janus kinase) inhibitor, showed efficacy in patients suffering from moderate-to-severe rheumatoid arthritis. In this paper, we present the data on the development and validation of a sensitive, selective and high-throughput LC-MS/MS (liquid chromatography with tandem mass spectrometry) method for the quantitation of filgotinib from rat dried blood spot (DBS) cards. To the DBS disc cards, 0.2% formic acid enriched with internal standard (IS) was added and sonicated. Thereafter the extraction of filgotinib and the IS (tofacitinib) was accomplished using ethyl acetate as an extraction solvent. The resolution of filgotinib and the IS was achieved on a Gemini C18 column with an isocratic mobile phase, which is a mixture of 0.2% formic acid:acetonitrile (20:80, v/v) at a flow-rate of 0.9 mL/min. The total run time was 2.90 min and the retention time of filgotinib and the IS was ~1.31 and 0.89 min, respectively. Filgotinib and the IS were analyzed using positive ion scan mode and parent-daughter mass to charge ion (m/z) transition of 426.3→291.3 and m/z 313.2→149.2, respectively, for quantitation. The calibration range was 1.37-1937 ng/mL. No matrix effect and carry over were observed. All the validation parameters met the acceptance criteria. The validated method has been applied to a pharmacokinetic study in rats. A good correlation between DBS and plasma concentrations for filgotinib was observed.
Collapse
Affiliation(s)
- Abhishek Dixit
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Bhavesh Babulal Gabani
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| |
Collapse
|
19
|
Dittakavi S, Mahadevan L, Chandrashekar DV, Bhamidipati RK, Suresh J, Dhakshinamoorthy S, Li Z, Baerenz F, Tennagels N, Mullangi R. Cover Image. Biomed Chromatogr 2020. [DOI: 10.1002/bmc.4846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
20
|
Zakkula A, Pulipati S, Dittakavi S, Bestha RM, Zainuddin M, Trivedi RK, Mullangi R. Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2020; 70:233-238. [PMID: 32289835 DOI: 10.1055/a-1141-3475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Filgotinib is a selective JAK1 (Janus kinase) inhibitor, filed in Japan for the treatment of rheumatoid arthritis. In this paper, we present the data of development and validation of a high-performance liquid chromatography (HPLC) method for the quantitation of filgotinib in mice plasma as per the FDA regulatory guideline. The method involves the extraction of filgotinib along with internal standard (IS, tofacitinib) from mice plasma (100 µL) using ethyl acetate as an extraction solvent. The chromatographic analysis was performed using an isocratic mobile phase comprising 10 mM ammonium acetate (pH 4.5) and acetonitrile (70:30, v/v) at a flow-rate of 0.8 mL/min on a Hypersil Gold C18 column. The UV detection wavelength was set at λmax 300 nm. Filgotinib and the IS eluted at 5.56 and 4.28 min, respectively with a total run time of 10 min. The calibration curve was linear over a concentration range of 0.05 to 5.00 μg/mL (r 2+=≥0.992). The intra- and inter-day precision and accuracy results were within the acceptable limits. Results of stability studies indicated that filgotinib was stable on bench-top, in auto-sampler, up to three freeze/thaw cycles and long-term storage at -80°C. The validated HPLC method was successfully applied to a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Shobha Pulipati
- Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, A.P, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ram Murthi Bestha
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ravi Kumar Trivedi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| |
Collapse
|
21
|
Zakkula A, Kurakula PK, Dittakavi S, Daram P, Bestha RM, Zainuddin M, Trivedi RK, Mullangi R. Validated HPLC method for quantification of copanlisib in mice plasma: application to a pharmacokinetic study. ADMET DMPK 2020; 8:113-121. [PMID: 35299776 PMCID: PMC8915597 DOI: 10.5599/admet.782] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 02/18/2020] [Indexed: 12/02/2022] Open
Abstract
Copanlisib is a pan phosphatidylinositol 3-kinase (PI3K) inhibitor approved for follicular lymphoma. In this paper, we present the data of development and validation of a high-performance liquid chromatography (HPLC) method for the quantitation of copanlisib in mice plasma as per the FDA regulatory guideline. The method involves the extraction of copanlisib along with internal standard (IS, enasidenib) from mice plasma (100 μL) using ethyl acetate as an extraction solvent. The chromatographic resolution of copanlisib and the IS was achieved on a Hypersil Gold C18 column maintained at 40 °C using a binary gradient mobile phase [10 mM ammonium formate (pH 4.0) and acetonitrile]. The flow-rate was 0.8 mL/min. For the detection of copanlisib and the IS, the photo-diode array detector was set at λmax 310 nm. Copanlisib and the IS eluted at 6.60 and 7.80 min, respectively with a total run time of 10 min. The calibration curve was linear over a concentration range of 50 to 5000 ng/mL for copanlisib (r2≥ 0.998). The results of intra- and inter-day accuracy and precision studies were within the acceptable limits. Copanlisib was stable on bench-top, in auto-sampler, up to three freeze/thaw cycle and long-term storage at -80 °C. The application of the validated method was shown in a mice pharmacokinetic study.
Collapse
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Pavan Kumar Kurakula
- Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur-515721, A.P, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Prasanthi Daram
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Ram Murthi Bestha
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Ravi Kumar Trivedi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
- *Corresponding Author: E-mail: ; Tel.: +91-80-66628339
| |
Collapse
|
22
|
Zakkula A, Gabani BB, Jairam RK, Kiran V, Todmal U, Mullangi R. Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability. Drug Dev Ind Pharm 2020; 46:498-504. [PMID: 32067499 DOI: 10.1080/03639045.2020.1730398] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Objective: The objective of the current research was to prepare self-micro-emulsifying drug delivery systems (SMEDDS) for BCS class II drug, nilotinib to enhance its oral bioavailability.Methodology: Different types of excipients like oil, surfactant, and co-surfactant were evaluated for drug solubility. Among the screened excipients, Capryol 90, Transcutol HP, and Tween 80 were selected as oil, co-surfactant, and surfactant, respectively, to construct a ternary phase diagram to identify a homogenous mixture. Characterization performed for the prepared SMEDDS for its particle size/droplet size, emulsification time, phase separation, droplet morphology, in vitro drug release, and oral bioavailability.Results: Prepared SMEDDS showed the highest of 87% drug release in in vitro drug release experiment. SMEDDS drug release was superior over suspension formulation, which could be attributed to oil/surfactant ratios and particle size of the SMEDDS. The acquired pharmacokinetic parameters indicate that twofold increase in systemic exposure of SMEDDS compared with nilotinib suspension formulation. A similar twofold increase in relative oral bioavailability was also observed when compared SMEDDS formulation with suspension formulation. Delayed Tmax (time to reach peak plasma concentrations) was observed with SMEDDS over suspension formulation, which was evident by slow rate of absorption of nilotinib from SMEDDS.Conclusion: This research demonstrated that SMEDDS could be an effective approach to improve solubility and oral bioavailability for the BCS class II poorly soluble nilotinib.
Collapse
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | | | - Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Umesh Todmal
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Bangalore, India
| |
Collapse
|
23
|
Dixit A, Kiran V, Gabani BB, Mohd Z, Trivedi RK, Mullangi R. Validated LC–MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. Biomed Chromatogr 2020; 34:e4802. [DOI: 10.1002/bmc.4802] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 01/22/2020] [Accepted: 01/27/2020] [Indexed: 12/19/2022]
Affiliation(s)
- Abhishek Dixit
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | - Vinay Kiran
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | | | - Zainuddin Mohd
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | | | - Ramesh Mullangi
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| |
Collapse
|
24
|
Gabani BB, Kiran V, Praharaj S, Srinivas NR, Mullangi R. Incurred sample reanalysis of cefuroxime in rabbit ocular tissues-A case study. Biomed Chromatogr 2020; 34:e4737. [PMID: 31950509 DOI: 10.1002/bmc.4737] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/22/2019] [Accepted: 10/25/2019] [Indexed: 01/20/2023]
Abstract
In this paper, we present the incurred sample reanalysis (ISR) data for cefuroxime in various ocular tissues of rabbits. Based on the cefuroxime concentration vs. time profile in various ocular tissues, three chosen time points enabled ISR assessment. Cefuroxime was quantitated in the ocular tissues using a published liquid chromatography-electrospray ionization/tandem mass spectrometry method operated under the multiple reaction-monitoring mode in positive ion mode. Regardless of the ocular tissue, the linearity range was 12.7-2760 ng/ml with a correlation coefficient (r2 ) of ≥0.996. All of the ISR samples representing various ocular tissues met the acceptance criteria. To the best of our knowledge, this is the first report showing the ISR of ocular tissues in any species.
Collapse
Affiliation(s)
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Yeshwanthpur, Bangalore, India
| | - Shuvranshu Praharaj
- Department of Biology, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Yeshwanthpur, Bangalore, India
| |
Collapse
|
25
|
Tripathy HK, Nair Manju SV, Zakkula A, Bestha RM, Dittakavi S, Mullangi R. Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2020; 70:101-106. [PMID: 31931548 DOI: 10.1055/a-1071-0849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Larotrectinib, is an orally active novel small molecule approved for the treatment of solid tumors in pediatrics and adult patients. It acts by inhibiting tropomyosin receptor kinase. In this paper, we report the development and validation of a high-performance liquid chromatography (HPLC) method for the quantitation of larotrectinib in mice plasma as per the FDA regulatory guideline. Plasma samples processing was accomplished through simple protein precipitation using acetonitrile enriched with internal standard (IS, enasidenib). The chromatographic analysis was performed using a gradient mobile phase comprising 10 mM ammonium acetate and acetonitrile at a flow-rate of 0.8 mL/min on an X-Terra Phenyl column. The UV detection wave length was set at λmax 262 nm. Larotrectinib and the IS eluted at 3.85 and 6.60 min, respectively with a total run time of 8.0 min. The calibration curve was linear over a concentration range of 0.20-5.00 μg/mL (r2=≥0.992). The intra- and inter-day precision and accuracy results were within the acceptable limits. Results of stability studies indicated that larotrectinib was stable on bench-top, in auto-sampler, up to three freeze/thaw cycles and long-term storage at -80°C. The validated HPLC method was successfully applied to a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Harsha K Tripathy
- Karnataka College of Pharmacy Bangalore, Medicinal Chemistry, Bangalore, India
| | - S V Nair Manju
- Karnataka College of Pharmacy Bangalore, Medicinal Chemistry, Bangalore, India
| | | | | | | | | |
Collapse
|
26
|
Dittakavi S, Mahadevan L, Chandrashekar DV, Bhamidipati RK, Suresh J, Dhakshinamoorthy S, Li Z, Baerenz F, Tennagels N, Mullangi R. High-throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry. Biomed Chromatogr 2019; 34:e4790. [PMID: 31883352 DOI: 10.1002/bmc.4790] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 12/19/2019] [Accepted: 12/20/2019] [Indexed: 12/26/2022]
Abstract
Ceramides are known to be involved in various biological processes with their physiological levels elevated in various disease conditions such as diabetes, Alzheimer's, atherosclerosis. To facilitate the rapid screening of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 inhibition in HepG2 cells, a RapidFire coupled to tandem mass spectrometry (RF-MS/MS) method has been developed. The RF platform provides an automated solid-phase extraction system that gave a throughput of 12.6 s per sample to an MS/MS system using electrospray ionization under the positive ion mode. Chromatographic separation of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 was achieved using a ternary gradient on C8 type E cartridge. The MS/MS ion transitions monitored were 538.2 → 264.2, 650.7 → 264.2, 648.6 → 264.2, 566.4 → 264.2, 510.4 → 264.2, 594.4 → 264.2, 622.5 → 264.2, and 552.3 → 250.2 for Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, d18:1/22:0, and the internal standard (Cer d17:1/18:0), respectively. The RF-MS/MS methodology showed an excellent performance with an average Z' value of 0.5-0.7. This is the first report of an RF-MS/MS assay for screening of ceramides which is amenable for high-throughput screening.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| | - Lavanya Mahadevan
- Department of Biology, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| | - Devaraj V Chandrashekar
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| | - Ravi Kanth Bhamidipati
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| | - Juluri Suresh
- Department of Biology, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| | | | - Ziyu Li
- Sanofi Research and Development, Industriepark Hoechst, Frankfurt am Main, Germany
| | - Felix Baerenz
- Sanofi Research and Development, Industriepark Hoechst, Frankfurt am Main, Germany
| | - Norbert Tennagels
- Sanofi Research and Development, Industriepark Hoechst, Frankfurt am Main, Germany
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bengaluru, India
| |
Collapse
|
27
|
P S S, Trivedi RK, Srinivas NR, Mullangi R. A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. Biomed Chromatogr 2019; 34:e4742. [PMID: 31749152 DOI: 10.1002/bmc.4742] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 10/24/2019] [Accepted: 10/30/2019] [Indexed: 12/31/2022]
Abstract
Quantitation of drugs used for the treatment of chronic lymphocytic leukemia in various biological matrices during both pre-clinical and clinical developments is very important, often in routine therapeutic drug monitoring. The first developed methods for quantitation were traditionally done on LC in combination with either UV or fluorescence detection. However, the emergence of LC with mass spectrometry in tandem in early 1990s has revolutionized the quantitation as it has provided better sensitivity and selectivity within a shorter run time; therefore it has become the choice of method for the analysis of various drugs. In this article, an overview of various bioanalytical methods (HPLC or LC-MS/MS) for the quantification of drugs for the treatment of chronic lymphocytic leukemia, along with applicability of these methods, is given.
Collapse
Affiliation(s)
- Suresh P S
- Jubilant Biosys, 2nd Stage, Bangalore, India
| | | | | | | |
Collapse
|
28
|
Dittakavi S, Hallur G, Purra BR, Kiran V, Zakkula A, Mullangi R. Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2019; 70:41-48. [PMID: 31652462 DOI: 10.1055/a-1024-3623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Enasidenib is a selective mutant isocitrate dehydrogenase 2 inhibitor approved for the treatment of relapsed and refractory acute myeloid leukemia patients. A sensitive and rapid method has been developed and validated as per regulatory guideline for the simultaneous quantitation of enasidenib and its active metabolite, AGI-16903 in mice plasma using an LC-MS/MS. Enasidenib and AGI-16903 along with internal standard were extracted from mice plasma using simple protein precipitation method. Chromatographic resolution of enasidenib, AGI-16903 and the internal standard (close analogue of AGI-16903) was achieved on a Chromolith RP-18e column using 0.2% formic acid:acetonitrile (15:85, v/v) as an eluent, which was delivered at a flow-rate of 1.2 mL/min. The MS/MS ion transitions monitored were m/z 474.1→267.2, 402.1→188.1 and 421.0→146.1 for enasidenib, AGI-16903 and the internal standard, respectively. The linearity range was 1.01-3023 ng/mL for both enasidenib and AGI-16903. The within-run and between-run accuracy and within-run and between-run precision were in the range of - 2.29 to 2.72 (as one value is in negative side). and 4.65-9.82%, respectively for enasidenib; 0.19-10.3 and 3.22-9.22%, respectively for AGI-16903. Both enasidenib and AGI-16903 were found to be stable in stability (up to three freeze-thaw cycles and for long-term at -80°C for 30 days) and processed (bench-top for 6 h and in in-injector for 24 h) samples. Application of the validated method was shown in a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Jubilant Biosys, Drug Metabolism and Pharmacokinetics, Bangalore, India.,Jubilant Biosys, Department of Medicinal Chemistry, Bangalore, India
| | | | - Buchi Reddy Purra
- Jubilant Biosys, Department of Medicinal Chemistry, Bangalore, India
| | - Vinay Kiran
- Jubilant Biosys, Drug Metabolism and Pharmacokinetics, Bangalore, India
| | - Ashok Zakkula
- Jubilant Biosys, Drug Metabolism and Pharmacokinetics, Bangalore, India
| | - Ramesh Mullangi
- Jubilant Biosys, Drug Metabolism and Pharmacokinetics, Bangalore, India
| |
Collapse
|
29
|
Zakkula A, Dittakavi S, Maniyar MM, Syed N, Sulochana SP, Zainuddin M, Mullangi R. Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study. Biomed Chromatogr 2019; 33:e4658. [DOI: 10.1002/bmc.4658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 07/12/2019] [Accepted: 07/15/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | | | | | - Naveem Syed
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | | | - Mohd Zainuddin
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | - Ramesh Mullangi
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| |
Collapse
|
30
|
Gabani BB, Sulochana SP, Kiran V, Todmal U, Mullangi R. Validated LC–ESI–MS/MS method for the determination of tunicamycin in rat plasma: Application to a pharmacokinetic study. Biomed Chromatogr 2019; 33:e4661. [DOI: 10.1002/bmc.4661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 07/10/2019] [Accepted: 07/15/2019] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - Vinay Kiran
- Drug Metabolism and PharmacokineticsJubilant Biosys Bangalore India
| | - Umesh Todmal
- Drug Metabolism and PharmacokineticsJubilant Biosys Bangalore India
| | - Ramesh Mullangi
- Drug Metabolism and PharmacokineticsJubilant Biosys Bangalore India
| |
Collapse
|
31
|
Sama V, Pagilla B, Chiluka R, Alvala R, Pola RK, Mullangi R. Bioenhancing effects of naringin on atrovastatin. ADMET DMPK 2019; 7:174-182. [PMID: 35350662 PMCID: PMC8957237 DOI: 10.5599/admet.647] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Revised: 03/18/2019] [Indexed: 11/20/2022] Open
Abstract
Naringin (CAS no: 10236-47-2) is a flavonone glycoside obtained from Citrus paradisi (grapefruit), a natural bioenhancer and reported to enhance the bioavailability of drugs by inhibiting cytochrome P450 and P-glycoprotein (P-gp). The aim of the present study was to investigate the effect of naringin on antihyperlipidemic properties of atorvastatin (AST) in tyloxapol induced hyperlipidemic rats and the effects were supported with measurement of plasma concentrations of AST by HPLC method. Animals received AST along with naringin (15 and 30 mg/kg) shown higher percent reduction in both cholesterol and triglycerides levels, when compared to animals received AST alone at dose of 25 and 50 mg/kg and it was found that the higher percent reduction in cholesterol and triglycerides was proportional to increase in plasma concentration of AST. From the results it is evident that the co-administration of naringin along with AST increased the plasma concentration of AST. The findings of the present study confirmed that naringin could be used as bioenhancer. The co-administration of AST and the diet with naringin (grapefruit) to the patients may potentiate the therapeutic efficacy of AST.
Collapse
Affiliation(s)
- Venkatesh Sama
- G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500028, India
- *Corresponding Author: E-mail: ; Tel.: +91-40-2351 7222
| | - Balaraju Pagilla
- G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500028, India
| | - Rajeswari Chiluka
- G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500028, India
| | - Ravi Alvala
- G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500028, India
| | - Ravi Kumar Pola
- G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500028, India
| | - Ramesh Mullangi
- JubilantBiosys, Industrial Suburb, Yeshwanthpur, Bangalore-566022, India
| |
Collapse
|
32
|
Jairam RK, Mallurwar SR, Gabani BB, Zakkula A, Kiran V, Dittakavi S, Sulochana SP, Mohd Z, Srinivas NR, Mullangi R. Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime. Xenobiotica 2019; 50:339-345. [PMID: 31144563 DOI: 10.1080/00498254.2019.1624872] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Cefuroxime is one of the widely used antibiotics. The objective of this study was to determine pharmacokinetics and disposition in various ocular tissues following topical (TOP), intracameral (IC) and intravitreal (IVT) administration of cefuroxime to rabbits.Following TOP, IC and IVT dosing plasma and various ocular tissues (aqueous humor (AH), vitreous humor (VH), conjunctiva, trabecular mesh (TM), lens and retina-choroid (RC)) were collected and analyzed to understand the disposition of cefuroxime. Postintravenous administration plasma samples were collected to determine the systemic pharmacokinetics.Post-TOP dosing cefuroxime concentrations were observed only in conjunctiva up to 48 h. IC administration showed cefuroxime concentrations in AH up to 8 h; in conjunctiva, TM and plasma, the concentration lasted up to 4 h and in RC and VH till 1 h. IVT administration of cefuroxime showed concentrations in all ocular tissues (up to 8 h) and lasted up to 48 h except in conjunctiva and RC.There was evidence that the mechanism(s) of cefuroxime entry into the eye by via IVT, IC and TOP routes is clearly different. The present ocular tissue data may aid clinicians for considering appropriate choice in the treatment of post-operative ocular complications due to bacterial infections including endophthalmitis.
Collapse
Affiliation(s)
- Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Sadanand R Mallurwar
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Bhavesh B Gabani
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Zainuddin Mohd
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Industrial Suburb, Yeshwanthpur, Bangalore, India
| |
Collapse
|
33
|
Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekhar DV, Todmal U, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R. Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. AAPS PharmSciTech 2019; 20:221. [PMID: 31214899 DOI: 10.1208/s12249-019-1434-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 05/23/2019] [Indexed: 11/30/2022] Open
Abstract
Fomepizole is used as an antidote to treat methanol poisoning due to its selectivity towards alcohol dehydrogenase. In the present study, the goal is to develop a method to predict the fomepizole human plasma concentration versus time profile based on the preclinical pharmacokinetics using the assumption of superimposability on simulated time course profiles of animals and humans. Standard allometric equations with/without correction factors were also assimilated in the prediction. The volume of distribution at steady state (Vss) predicted by simple allometry (57.55 L) was very close to the reported value (42.17 L). However, clearance (CL) prediction by simple allometry was at least 3-fold higher to the reported value (33.86 mL/min); hence, multiple correction factors were used to predict the clearance. Both brain weight and maximum life span potential could predict the CL with 1.22- and 1.01-fold difference. Specifically, the predicted Vss and CL values via interspecies scaling were used in the prediction of series of human intravenous pharmacokinetic parameters, while the simulation of human oral profile was done by the use of absorption rate constant (Ka) from dog following the applicability of human bioavailability value scaled from dog data. In summary, the findings indicate that the utility of diverse allometry approaches to derive the human pharmacokinetics of fomepizole after intravenous/oral dosing.
Collapse
Affiliation(s)
- Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India
| | | | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India
| | - Devaraj V Chandrasekhar
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India
| | - Umesh Todmal
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India
| | - Ravi Kanth Bhamidipati
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India
| | - Wolfgang Richter
- TUBE Pharmaceuticals GmbH, Leberstr. 20, A-1110, Vienna, Austria
| | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India.
| |
Collapse
|
34
|
Gabani BB, Todmal U, Saini NK, Balakrishna VA, Sulochana SP, Timmapuram A, Zainuddin M, Balaji N, Shuvranshu P, Srinivas NR, Mullangi R. Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague–Dawley rats. Xenobiotica 2019; 50:135-144. [DOI: 10.1080/00498254.2019.1599148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
| | - Umesh Todmal
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India
| | | | | | | | - Ashok Timmapuram
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India
| | - Narayanan Balaji
- Department of Analytical Chemistry, Jubilant Biosys, Bangalore, India
| | | | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India
| |
Collapse
|
35
|
Dittakavi S, Jat RK, Mallurwar SR, Jairam RK, Mullangi R. Validated LC-ESI-MS/MS method for the determination of ivosidenib in 10 µL mice plasma: application to a pharmacokinetic study. ADMET DMPK 2019; 7:131-139. [PMID: 35350545 PMCID: PMC8957231 DOI: 10.5599/admet.648] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 02/04/2019] [Indexed: 11/18/2022] Open
Abstract
A simple, selective and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of ivosidenib in mice plasma using warfarin as an internal standard (I.S.) as per regulatory guideline. Sample preparation was accomplished through a simple protein precipitation process. Chromatography of ivosidenib and the I.S. was achieved on an Atlantis dC18 column using an isocratic mobile phase comprising 0.2 % formic acid in water and acetonitrile (25:75, v/v) delivered at a flow rate of 1.0 mL/min. LC-MS/MS was operated under the multiple reaction-monitoring mode (MRM) using the electrospray ionization technique in positive ion mode and the transitions of m/z 583.1→186.1 and m/z 309.2→251.3 were used to quantitate ivosidenib and the I.S, respectively. The total chromatographic run time was 2.0 min. Linearity was established in the concentration range of 1.10-3293 ng/mL (r2>0.99). The intra- and inter-day accuracy and precision for ivosidenib in mice plasma were in the range of 5.72-9.91 and 5.90-10.7 %, respectively. Ivosidenib was found to be stable on bench-top for 6 h, up to three freeze-thaw cycles, in in-injector for 24 h and for one month at -80 °C. The applicability of the validated method has been demonstrated in a mice pharmacokinetic study. Following intravenous (2 mg/kg) and oral (5 mg/kg) administration of ivosidenib to mice, concentrations were quantifiable up to 24 and 48 h, respectively. The bioavailability was 61 %.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
- Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu-Churu Road, Chudela, Jhunjhunu-333001, Rajasthan
| | - Rakesh Kumar Jat
- Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu-Churu Road, Chudela, Jhunjhunu-333001, Rajasthan
| | | | - Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore-560 022, India
- *Corresponding Author: E-mail: ; Tel.: +91-80-66628339
| |
Collapse
|
36
|
Dittakavi S, Jat RK, Mullangi R. Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2019; 69:505-511. [DOI: 10.1055/a-0857-6591] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
AbstractIvosidenib is an approved drug for relapsed or refractory IDH1 mutant AML patients. The goal of the present work is to develop and validate an LC-MS/MS method for the quantitation of ivosidenib in mice dried blood spots (DBS) as per regulatory guideline in the linearity range of 1.10–3293 ng/mL. To date there is no bioanalytical method reported for quantitation of ivosidenib. The chromatographic resolution of ivosidenib and internal standard (warfarin) was achieved on a C18 column with an isocratic mobile phase. All validation parameters met the acceptance criteria. The intra- and inter-day precision was in the range of 2.79–10.5 and 5.76–9.02%, respectively. Ivosidenib was stable for 3 freeze/thaw cycles, up to 7 days at room temperature and for one month at −80°C. The applicability of the validated method is shown in a mice pharmacokinetic study. Ivosidenib was quantifiable up to 24 and 36 h following intravenous and oral administration to mice, respectively. The oral bioavailability was 48%. Comparison of DBS vs. plasma concentrations of ivosidenib showed excellent correlation, indicating DBS can be used as an alternative for plasma for pharmacokinetic analysis.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
- Principal and Professor, Head of Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
| | - Rakesh Kumar Jat
- Principal and Professor, Head of Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
| |
Collapse
|
37
|
Dittakavi S, Jat RK, Mullangi R. Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. Biomed Chromatogr 2019; 33:e4491. [PMID: 30663096 DOI: 10.1002/bmc.4491] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 01/10/2019] [Accepted: 01/11/2019] [Indexed: 11/09/2022]
Abstract
A simple, sensitive and rapid assay method has been developed and validated as per regulatory guidelines for the estimation of enasidenib on mouse dried blood spots (DBS) using liquid chromatography coupled to tandem mass spectrometry with electrospray ionization in the positive-ion mode. The method employs liquid extraction of enasidenib from DBS disks of mouse whole blood followed by chromatographic separation using 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 1.0 mL/min on an Atlantis dC18 column with a total run time of 2.0 min. The MS/MS ion transitions monitored were m/z 474.0 → 267.1 for enasidenib and m/z 309.2 → 251.3 for the internal standard (warfarin). The assay was linear in the range of 1.01-3044 ng/mL. The within-run and between-run precisions were in the range of 3.18-9.06 and 4.66-8.69%, respectively. Stability studies showed that enasidenib was stable on DBS cards for 1 month. This novel method has been applied to analyze the DBS samples of enasidenib obtained from a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Sreekanth Dittakavi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India.,Principal and Professor, Head of Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
| | - Rakesh Kumar Jat
- Principal and Professor, Head of Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Bangalore, India
| |
Collapse
|
38
|
Sulochana S, Daram P, Srinivas NR, Mullangi R. Review of DBS methods as a quantitative tool for anticancer drugs. Biomed Chromatogr 2018; 33:e4445. [DOI: 10.1002/bmc.4445] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 11/09/2018] [Accepted: 11/13/2018] [Indexed: 12/30/2022]
Affiliation(s)
| | - Prasanthi Daram
- Jubilant Biosys, 2nd Stage, Industrial Suburb; Bangalore India
| | | | - Ramesh Mullangi
- Jubilant Biosys, 2nd Stage, Industrial Suburb; Bangalore India
| |
Collapse
|
39
|
Zakkula A, Kiran V, Todmal U, Sulochana SP, Mullangi R. RP-HPLC-UV Method for Simultaneous Quantification of Second Generation Non-Steroidal Antiandrogens Along with their Active Metabolites in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2018; 69:537-544. [PMID: 30536259 DOI: 10.1055/a-0790-8309] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A simple, specific and reproducible high-performance liquid chromatography (HPLC) assay method has been developed and validated for the quantitation of second generation antiandrogens and their active metabolites namely apalutamide, enzalutamide, N-desmethylenzalutamide (active metabolite of enzalutamide), darolutamide and ORM-15341 (active metabolite of darolutamide) in mice plasma. The method involves extraction of apalutamide, enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 along with internal standard (IS) from 100 µL mice plasma through a simple protein precipitation process. The chromatographic analysis was performed on a Waters Alliance HPLC system using a gradient mobile phase (comprising 10 mM ammonium acetate and acetonitrile in a flow-gradient) and X-Terra Phenyl column. The UV detection wave length was set at λmax 250 nm. Apalutamide, enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 and the IS eluted at 13.6, 11.4, 9.68, 6.11, 6.93 and 4.69 min, respectively with a total run time of 15 min. Method validation was performed as per regulatory guidelines and the results met the acceptance criteria. The calibration curve was linear over a concentration range of 209 - 5215 ng/mL (r 2=0.998). The intra- and inter-day precisions were in the range of 0.56-13.5 and 1.04-13.9%, respectively. The validated HPLC method was successfully applied to a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Ashok Zakkula
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Umesh Todmal
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore, India
| |
Collapse
|
40
|
Balaji N, Gabani BB, Todmal U, Sulochana SP, Saini NK, Chandran R, Mullangi R. Enantioselective LC‐ESI‐MS/MS determination of dropropizine enantiomers in rat plasma and application to a pharmacokinetic study. Biomed Chromatogr 2018; 33:e4434. [DOI: 10.1002/bmc.4434] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 09/30/2018] [Accepted: 10/28/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Narayanan Balaji
- Department of Analytical ChemistryJubilant Biosys Ltd Bangalore India
| | | | - Umesh Todmal
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| | | | | | - Rajesh Chandran
- Department of Analytical ChemistryJubilant Biosys Ltd Bangalore India
| | - Ramesh Mullangi
- Drug Metabolism and PharmacokineticsJubilant Biosys Ltd Bangalore India
| |
Collapse
|
41
|
Dittakavi S, Mullangi R. LC‐ESI‐MS/MS determination of copanlisib, a novel PI3K inhibitor in plasma and its application to a pharmacokinetic study in mice. Biomed Chromatogr 2018; 33:e4460. [DOI: 10.1002/bmc.4460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 11/28/2018] [Accepted: 12/03/2018] [Indexed: 11/08/2022]
Affiliation(s)
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd Bangalore India
| |
Collapse
|
42
|
Saini NK, Sulochana SP, Kiran V, Zainuddin M, Mullangi R. Cover Image. Biomed Chromatogr 2018. [DOI: 10.1002/bmc.4405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
43
|
Saini NK, Sulochana SP, Zainuddin M, Mullangi R. Development and validation of a novel method for simultaneous quantification of enzalutamide, darolutamide and their active metabolites in mice dried blood spots using LC-MS/MS: Application to pharmacokinetic study in mice. ADMET DMPK 2018. [DOI: 10.5599/admet.557] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A simple, sensitive and rapid assay method has been developed and validated for the estimation of enzalutamide, N-desmethylenzalutamide (active metabolite of enzalutamide), darolutamide and ORM-15341 (active metabolite of darolutamide) on mice dried blood spots (DBS) using liquid chromatography coupled to tandem mass spectrometry with electro spray ionization in the positive-ion mode. The method utilizes liquid extraction of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 from 3 mm punched disks from DBS cards (spiked or study samples). The extracted sample was chromatographed using an isocratic mobile phase (0.2 % formic acid : acetonitrile; 30:70, v/v) on an Atlantis dC18 column. The total run time was 2.5 min. The MS/MS ion transitions monitored were m/z 465 → m/z 209, m/z 451 → m/z 195, m/z 399 → m/z 178, m/z 397 → m/z 194 and m/z 481 → m/z 453 for enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 and the IS (apalutamide-d3), respectively. Method validation was performed as per regulatory guideline. The assay had a good linearity over the range of 0.93-2000 ng/mL. The intra- and inter-batch accuracy and precision (%RE & RSD) across quality controls met the acceptance criteria for all the analytes. Stability studies showed that all the analytes were stable on DBS cards for one month. This novel method has been applied to analyze the DBS samples of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 obtained from a pharmacokinetic study in mice.
Collapse
|
44
|
Dixit A, Mallurwar SR, Sulochana SP, Zainuddin M, Mullangi R. Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC–ESI–MS/MS: Application to Pharmacokinetic Study in Mice. Drug Res (Stuttg) 2018; 69:330-336. [PMID: 30193392 DOI: 10.1055/a-0677-3066] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
AbstractA simple, sensitive and rapid assay method has been developed and validated as per regulatory guideline for the estimation of tofacitinib on mice dried blood spots (DBS) using liquid chromatography coupled to tandem mass spectrometry with electro spray ionization in the positive-ion mode. The method employs liquid extraction of tofacitinib from DBS disk of mice whole blood followed by chromatographic separation using 5 mM ammonium acetate (pH 6.5):acetonitrile (20:80, v/v) at a flow rate of 0.60 mL/min on an X-Terra Phenyl column with a total run time 2.5 min. The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (13C3,
15N-tofacitinib). The assay was linear in the range of 0.99–1980 ng/mL. The intra- and inter-day precision was in the range of 1.17–10.3 and 3.37–10.9%, respectively. Stability studies showed that tofacitinib was stable on DBS cards for one month. This novel method has been applied to analyze the DBS samples of tofacitinib obtained from a pharmacokinetic study in mice.
Collapse
Affiliation(s)
- Abhishek Dixit
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
| | | | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
| |
Collapse
|
45
|
Saini NK, Sulochana SP, Kiran V, Zainuddin M, Mullangi R. A novel dried blood spot LC-MS/MS method for the quantification of apalutamide in mouse whole blood: Application to pharmacokinetic study in mice. Biomed Chromatogr 2018; 32:e4344. [DOI: 10.1002/bmc.4344] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 07/04/2018] [Accepted: 07/05/2018] [Indexed: 12/24/2022]
Affiliation(s)
- Neeraj Kumar Saini
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2 Stage, Industrial Suburb; Bangalore India
| | - Suresh P. Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2 Stage, Industrial Suburb; Bangalore India
| | - Vinay Kiran
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2 Stage, Industrial Suburb; Bangalore India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2 Stage, Industrial Suburb; Bangalore India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, 2 Stage, Industrial Suburb; Bangalore India
| |
Collapse
|
46
|
Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekar DV, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R. Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. Drug Res (Stuttg) 2018; 69:32-39. [PMID: 29996173 DOI: 10.1055/a-0640-8977] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Bendamustine, an alkylating anticancer agent, is used to treat chronic lymphocytic leukemia by intravenous infusion alone or in combination. The work aimed to develop a method to predict time vs. concentration profile for humans based on preclinical pharmacokinetics using the assumption of superimposability of normalized time course profiles of animals and humans. Standard allometric equations with/without correction factors (CF) were also used in prediction. The Vss was predicted by simple allometry of 0.312W0.871 (r2=0.987), where W is body weight; predicted Vss (19.71 L) was similar to the reported value (20.10 L). However, CL prediction involved both simple and CF allometry. Best proximity CL (543 vs. 598 mL/min) was obtained with maximum life span correction (MLP) [2.46W1.215 (r2=0.988)]. Normalized curves were obtained by normalizing the time (with mean residence time) vs. concentration (with dose/Vss) in animal species. The concentration vs. time profile in humans after intravenous infusion was then simulated using normalized curve for each animal species and the values of CL and Vss were predicted for humans. In summary the findings indicate that normalized time course approach could predict the bendamustine human pharmacokinetics and such an approach could be prospectively applied for analog drugs of this class.
Collapse
Affiliation(s)
- Ravi Kumar Jairam
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | | | - Suresh P Sulochana
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Devaraj V Chandrasekar
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | - Ravi Kanth Bhamidipati
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| | | | | | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Industrial Suburb, Yeshwanthpur, Bangalore, India
| |
Collapse
|
47
|
Sulochana SP, Saini NK, Daram P, Polina SB, Mullangi R. Validation of an LC–MS/MS method for simultaneous quantitation of enzalutamide, N -desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study. J Pharm Biomed Anal 2018; 156:170-180. [DOI: 10.1016/j.jpba.2018.04.038] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Revised: 04/20/2018] [Accepted: 04/22/2018] [Indexed: 01/29/2023]
|
48
|
Hallur G, Purra BR, Sulochana SP, Saini NK, Daram P, Zainuddin M, Mullangi R. Validation of an LC-ESI–MS/MS method for the determination of apalutamide, a novel non-steroidal anti-androgen in mice plasma and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal 2018. [DOI: 10.1016/j.jpba.2018.02.054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
49
|
Balaji N, Sulochana SP, Saini NK, A SK, Mullangi R. Validated Chiral LC-ESI-MS/MS Method for the Simultaneous Quantification of Darolutamide Diastereomers and Its Active Metabolite in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg) 2018; 68:615-624. [PMID: 29558780 DOI: 10.1055/a-0580-7218] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
A simple, selective and reliable LC-MS/MS method was developed and validated for the simultaneous quantitation of darolutamide diastereomers (diastereomer-1 and diastereomer-2) and its active metabolite i. e. ORM-15341 in mice plasma using warfarin as an internal standard (IS) as per the regulatory guidelines. Plasma samples were extracted by liquid-liquid extraction and the chromatographic separation was achieved on a Chiralpak IA column with an isocratic mobile phase 5 mM ammonium acetate:absolute alcohol (20:80, v/v) at a flow rate of 1.0 mL/min. Detection and quantitation was done by multiple reaction monitoring on a triple quadrupole mass spectrometer following the transitions: m/z 397→202, 395→202 and 307→250 for darolutamide diastereomers, ORM-15341 and the IS, respectively in the negative ionization mode. The calibration curves were linear (r>0.992) in the range of 100-2400 ng/mL for all the analytes. The intra- and inter-day precisions were in the range of 1.25-10.2 and 1.58-12.3; 2.85-5.68 and 1.85-9.58; 2.34-12.1 and 2.58-7.38 for diastereomer-1, diastereomer-2 and ORM-15341, respectively. Both diastereomers and ORM-15341 were found to be stable under different stability conditions. The validated method was applied to a pharmacokinetic study in mice.
Collapse
Affiliation(s)
| | - Suresh P Sulochana
- Analtyical Chemistry, Jubilant Biosys Ltd, Yeshwanthpur, Bangalore, India
| | - Neeraj Kumar Saini
- Analtyical Chemistry, Jubilant Biosys Ltd, Yeshwanthpur, Bangalore, India
| | - Siva Kumar A
- Environmental & Analytical Division, SAS, VIT University, Vellore, India
| | - Ramesh Mullangi
- Analtyical Chemistry, Jubilant Biosys Ltd, Yeshwanthpur, Bangalore, India
| |
Collapse
|
50
|
Hallur G, Tamizharasan N, Sulochana SP, Saini NK, Zainuddin M, Mullangi R. LC-ESI–MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal 2018; 149:358-364. [DOI: 10.1016/j.jpba.2017.11.022] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 11/02/2017] [Accepted: 11/05/2017] [Indexed: 12/21/2022]
|